Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :30238076
Publication Date : //

Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis.


Surgical injury can be a life-threatening complication, not only due to the injury itself, but also due to immune responses to the injury and subsequent development of infections, which readily result in sepsis. Sepsis remains the leading cause of death in most intensive care units. Unfavorable outcomes of several high-profile trials in the treatment of sepsis have led researchers to state that sepsis studies need a new direction. The immune response that occurs during sepsis is characterized by a cytokine-mediated hyper-inflammatory phase, which most patients survive, and a subsequent immunosuppressive phase. Therefore, therapies that improve host immunity might increase the survival of patients with sepsis. Many mechanisms are responsible for sepsis-induced immunosuppression, including apoptosis of immune cells, increased regulatory T cells and expression of programmed cell death 1 on CD4 T cells, and cellular exhaustion. Immunomodulatory molecules that were recently identified include interleukin-7, interleukin-15, and anti-programmed cell death 1. Recent studies suggest that immunoadjuvant therapy is the next major advance in sepsis treatment.

Authors : Ono Satoshi , Tsujimoto Hironori , Hiraki Shuichi , Aosasa Suefumi ,

Related products :

Catalog number Product name Quantity
DSEPI-123-V Human Sample (Sepsis) Individual unit
DSEPI-123-E Human Sample (Sepsis) Individual 5ml
DSEPI-123-V Human Sample (Sepsis) Individual 1unit
DSEPI-123-X Human Sample (Sepsis) Individual 1ml
DSEPI-123-X Human Sample (Sepsis) Individual 5 ml
DSEPI-123-V Human Sample (Sepsis) Individual 1 unit
DSEPI-123-E Human Sample (Sepsis) Individual 5 ml
orb61235 CP-690550 Tofacitinib is a drug being investigated by Pfizer for the treatment of rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the 10 mg
29-961 Transport of folate compounds into mammalian cells can occur via receptor-mediated or carrier-mediated mechanisms. A functional coordination between these 2 mechanisms has been proposed to be the meth 0.1 mg
EIAAB12657 EI24,Etoposide-induced protein 2.4 homolog,Homo sapiens,Human,p53-induced gene 8 protein,PIG8
EIAAB42358 12 kDa TGF-beta-1-induced antiapoptotic factor,Homo sapiens,Human,TGFB1-induced anti-apoptotic factor 1,TIAF1
15-288-21112 TGFB1-induced anti-apoptotic factor 1 - 12 kDa TGF-beta1-induced antiapoptotic factor Polyclonal 0.1 mg
15-288-21112 TGFB1-induced anti-apoptotic factor 1 - 12 kDa TGF-beta1-induced antiapoptotic factor Polyclonal 0.05 mg
EIAAB12656 Ei24,Etoposide-induced protein 2.4,Mouse,Mus musculus,p53-induced gene 8 protein,Pig8
EIAAB24781 Homo sapiens,Human,MDIG,MINA,MINA53,Mineral dust-induced gene protein,MYC-induced nuclear antigen,NO52,Nucleolar protein 52
S-4000-005 Modification Buffer (10X) 5 x 1.5 mL
Methylamp DNA Modification Kit (80 reactions)
P-1008-2 Methylamp 96 DNA Modification Kit 192 samples
P-1001-2 Methylamp DNA Modification Kit 80 reactions
P-1001-2 Methylamp DNA Modification Kit 80 samples
P-1026-050 BisulFlash DNA Modification Kit 50 reactions
CMP26-050 Ham's F-12 (Kaighn's Modification) 50L
P-1001-1 Methylamp DNA Modification Kit 40 samples
CMP26-001 Ham's F-12 (Kaighn's Modification) 10x1L
P-1008-1 Methylamp 96 DNA Modification Kit 96 samples


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur